Erdosteine

Jump to: navigation, search
Erdosteine
Erdosteine.png
Clinical data
ATC code
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC8H11NO4S2
Molar mass249.309 g/mol

WikiDoc Resources for Erdosteine

Articles

Most recent articles on Erdosteine

Most cited articles on Erdosteine

Review articles on Erdosteine

Articles on Erdosteine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Erdosteine

Images of Erdosteine

Photos of Erdosteine

Podcasts & MP3s on Erdosteine

Videos on Erdosteine

Evidence Based Medicine

Cochrane Collaboration on Erdosteine

Bandolier on Erdosteine

TRIP on Erdosteine

Clinical Trials

Ongoing Trials on Erdosteine at Clinical Trials.gov

Trial results on Erdosteine

Clinical Trials on Erdosteine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Erdosteine

NICE Guidance on Erdosteine

NHS PRODIGY Guidance

FDA on Erdosteine

CDC on Erdosteine

Books

Books on Erdosteine

News

Erdosteine in the news

Be alerted to news on Erdosteine

News trends on Erdosteine

Commentary

Blogs on Erdosteine

Definitions

Definitions of Erdosteine

Patient Resources / Community

Patient resources on Erdosteine

Discussion groups on Erdosteine

Patient Handouts on Erdosteine

Directions to Hospitals Treating Erdosteine

Risk calculators and risk factors for Erdosteine

Healthcare Provider Resources

Symptoms of Erdosteine

Causes & Risk Factors for Erdosteine

Diagnostic studies for Erdosteine

Treatment of Erdosteine

Continuing Medical Education (CME)

CME Programs on Erdosteine

International

Erdosteine en Espanol

Erdosteine en Francais

Business

Erdosteine in the Marketplace

Patents on Erdosteine

Experimental / Informatics

List of terms related to Erdosteine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Erdosteine is a mucolytic. Erdosteine is a thiol derivative developed for the treatment of chronic obstructive bronchitis, including acute infective exacerbation of chronic bronchitis. Erdosteine contains 2 blocked sulfhydryl groups which are released following first-pass metabolism. The 3 active metabolites exhibit mucolytic and free radical scavenging activity. Erdosteine modulates mucus production and viscosity and increases mucociliary transport, thereby improving expectoration. It also exhibits inhibitory activity against the effects of free radicals produced by cigarette smoke. Clinical studies in patients with chronic obstructive lung disease have demonstrated the efficacy and tolerability of erdosteine. Erdosteine 300mg twice daily reduced cough (both frequency and severity) and sputum viscosity more quickly and more effectively than placebo and reduced the adhesivity of sputum more effectively than ambroxol 30mg twice daily. Co-administration of erdosteine and amoxicillin in patients with acute infective exacerbation of chronic bronchitis resulted in higher concentrations of the antibiotic in the sputum, leading to earlier and more pronounced amelioration of clinical symptoms compared with placebo. Erdosteine is associated with a low incidence of adverse events, most of which are gastrointestinal and generally mild.

References


Linked-in.jpg